Stock Events

Stock Events

Iovance Biotherapeutics 

€7.13
435
-€0.36-4.81%Friday 16:30

Statistics

Day High
7.09
Day Low
6.89
52W High
14.88
52W Low
6.89
Volume
-
Avg. Volume
-
Mkt Cap
3.23B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q2 2026
Next
-0.12
-0.1
-0.09
-0.07
Expected EPS
-0.07484326688
Actual EPS
N/A

Financials

-149.7%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
227.88MRevenue
-341.13MNet Income

Analyst Ratings

$10.45Average Price Target
The highest estimate is ⁦15.18⁩.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2LB.XETRA. It's not an investment recommendation.
NVIDIA
95
NVDA
Amazon
78
AMZN
Microsoft
68
MSFT
Apple
62
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space for cancer, particularly with its CAR-T and TCR therapies.
Novartis
NVS
Mkt Cap303.67B
Novartis is a leader in CAR-T cell therapy for cancer, directly competing with Iovance's TIL-based therapies.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb, with its acquisition of Celgene, has a strong presence in the immuno-oncology market, competing with Iovance's cancer therapies.
Allogene Therapeutics
ALLO
Mkt Cap407.68M
Allogene Therapeutics focuses on allogeneic CAR-T therapies for cancer, offering an alternative to Iovance's autologous TIL therapies.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is involved in gene editing and CAR-T cell therapies for cancer, presenting a competitive edge in the innovative treatment market against Iovance.
Precigen
PGEN
Mkt Cap2.48B
Precigen focuses on gene and cell therapies, including CAR-T, which competes with Iovance's TIL therapy in the oncology space.

About

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Show More
CEO
Frederick G. Vogt
Employees
975
Country
United States
ISIN
US4622601007
WKN
000A2DT49

Listings

MI
IT
1IOVA.MI
STU
DE
2LB.STU
LSE
GB
0JDK.LSE
MU
DE
2LB.MU

0 Comments

Share your thoughts

FAQs

What is Iovance Biotherapeutics stock price today?▼
The current price of 2LB.XETRA is €7.13 EUR — it has decreased by -4.81% in the past 24 hours. Watch Iovance Biotherapeutics stock price performance more closely on the chart.
What is Iovance Biotherapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Iovance Biotherapeutics stocks are traded under the ticker 2LB.XETRA.
What is Iovance Biotherapeutics market cap?▼
Today Iovance Biotherapeutics has the market capitalization of 3.23B
When is the next Iovance Biotherapeutics earnings date?▼
Iovance Biotherapeutics is going to release the next earnings report on March 2, 2027.
What is Iovance Biotherapeutics revenue for the last year?▼
Iovance Biotherapeutics revenue for the last year amounts to 227.88M EUR.
What is Iovance Biotherapeutics net income for the last year?▼
2LB.XETRA net income for the last year is -341.13M EUR.
How many employees does Iovance Biotherapeutics have?▼
As of November 8, 2026, the company has 975 employees.
In which sector is Iovance Biotherapeutics located?▼
Iovance Biotherapeutics operates in the Health & Wellness sector.
When did Iovance Biotherapeutics complete a stock split?▼
Iovance Biotherapeutics has not had any recent stock splits.
Where is Iovance Biotherapeutics headquartered?▼
Iovance Biotherapeutics is headquartered in SAN CARLOS, United States.